scholarly journals The Effect of Infusion Speed on Nephrotoxicity in Patients Receiving Colistine Treatment in Oncology Hospital

2019 ◽  
Vol 24 (2) ◽  
pp. 87-92
Author(s):  
Arif Doğan Habiloğlu ◽  
Göknur Yapar Toros ◽  
Tuğba Aşkın ◽  
Yeliz İrem Tunçel ◽  
Fazilet Duygu ◽  
...  
Keyword(s):  
Infusion Speed

scholarly journals Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Saori Fukui ◽  
Mitsuru Seki ◽  
Takaomi Minami ◽  
Kazuhiko Kotani ◽  
Kensuke Oka ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Adverse Events ◽  
Intravenous Immunoglobulin ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Link Type ◽  
Cell Counts ◽  
Infusion Speed ◽  
Ivig Administration

Abstract Background High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10–24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported. In this study, we evaluated the differences in efficacy and safety between two different IVIG administration speeds. Methods This was a multicenter, unblinded, randomized controlled study. Patients newly diagnosed with KD were randomized into two groups: one who received IVIG over 12 h (12H group, double speed), and one that received IVIG over 24 h (24H group, reference speed). The endpoints included the duration of fever, incidence of coronary artery abnormalities (CAAs) and of adverse events. Laboratory data were evaluated before and after IVIG administration. Results A total of 39 patients were enrolled. There was no difference between groups in fever duration after the initiation of IVIG (21 h vs. 21.5 h, p = 0.325), and no patient experienced CAAs. Two adverse events were observed in the 12H group (elevation of aspartate aminotransferase and vomiting), however no severe adverse events requiring treatments or extension of hospital stay were observed in either group. After initial IVIG administration, the change ratio of inflammatory markers, such as white blood cell counts, neutrophils, C-reactive protein, and albumin, did not show significant differences between the two groups. On the other hand, a greater increase of serum immunoglobulin G from its baseline level was observed in the 24H group compared to the 12H group (3037 ± 648 mg/dl vs. 2414 ± 248 mg/dl, p < 0.01). Conclusion The efficacy and safety of IVIG administered over 12 h (double speed) were similar to those administered over 24 h (reference speed). Trial registration University Hospital Medical Information Network (UMIN000014665). Registered 27 July 2014 – Prospectively registered, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000017058

Infusion Speed-Escalation Trial To Give Full-Dose Rituximab in One Hour without Steroids Pre-Medication.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2451-2451 ◽  
Author(s):  
Michele Ghielmini ◽  
Laura Negretti ◽  
Erika Lerch ◽  
Barbara Roth ◽  
Michèle Voegeli ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Side Effects ◽  
Single Agent ◽  
Large Cell ◽  
Initial Speed ◽  
Serious Adverse Events ◽  
Pressure Drops ◽  
To Receive ◽  
Infusion Speed ◽  
Lymphoma Type

Abstract The first administration of rituximab can cause important side effects due to cytokine release into the blood. It is therefore recommended to administer it over 4–6 hours. According to the manufacturer subsequent doses can be given in approximately 3 hours, but this is demanding for the patient (pt) and facilities and resources-consuming. A Canadian study has recently shown that rituximab can be given safely over 90 minutes from the second administration in combination with CHOP, provided that steroids and chemotherapy are administered before the antibody. We are conducting an infusion speed-escalation trial to verify if rituximab can be given in one hour without steroids pre-medication, in pts having received at least two previous doses of rituximab (with or without chemotherapy) in the previous 3 months. Further inclusion criteria include a normal cardiac function as evaluated by ECG and echocardiography. Cohorts of 3 patients are assigned to receive rituximab at a given initial infusion speed, to be increased by 100 mg /hour every 30 minutes. All receive standard anti-hystamine and paracetamol pre-medication. At every subsequent rituximab administration the initial speed is increased by 100 mg/h (intra-patient speed-escalation). If a pt experiences serious adverse events (SAE), then 6 pts are treated in the same cohort, in case of SAE in 2 of them the trial is discontinued. In each new cohort the initial speed is 100 mg/hr higher than in the previous cohort. Pts are monitored every 15 minutes for symptoms, blood pressure and hearth rate, hourly for temperature and an ECG is performed after treatment. For patients receiving chemo-immunotherapy, rituximab is given first and chemotherapy only later on the same day. Fifteen pts have so far been included (14 evaluable), with the first 4 cohorts complete. Median age was 60 (range 41–76), lymphoma type was diffuse large cell (8 pts), follicular (4 pts) and other indolent (3 pts). Two patients were treated with single agent rituximab and 12 in combination with chemotherapy. The median time from the last rituximab to inclusion in the study was 3 weeks (range 1–11). Overall, 3 cycles were given at a starting infusion speed of 200 mg/hr, 7 cycles at 300 mg/hr, 11 cycles at 400 mg/hr, 11 cycles at 500 mg/hr, 8 cycles at 600 mg/hr and 7 cycles at 700 mg/hr. The latter schedule allowed the administration of the whole prescribed drug in one hour. All pts tolerated the increased-speed infusion without major side effects. The blood pressure dropped by a median 10–15% of baseline, without symptoms and without significant differences between cohorts. The highest blood pressure drops were of respectively 25% and 29% without symptoms and spontaneously resolving within 15 minutes. There was no variation in the hearth frequency and no elevation of body temperature above 37°C. No relevant ECG changes were seen. We conclude that rituximab can be given in one hour without steroids pre-medication in pts who have already received at least two previous rituximab doses. The study is ongoing to evaluate the maximum infusion speed and will further explore if the latter is applicable from the second infusion on.

In Vitro and in Vivo Measurement of Total Antiplasmin Activity

1977 ◽  
Vol 37 (02) ◽  
pp. 216-221 ◽  
Author(s):  
Osamu Matsuo ◽  
Hisashi Mihara
Keyword(s):  
Plasma Volume ◽  
Fibrinolytic Activity ◽  
Mean Value ◽  
Rabbit Plasma ◽  
In Vivo Measurement ◽  
The Mean ◽  
Infusion Speed

SummaryTotal antiplasmin was measured in vitro and in vivo. In the former case, rabbit plasma was mixed with various concentrations of Urokinase (UK) and the least concentration for appearance of fibrinolytic activity was estimated. This concentration was multiplied by the plasma volume of the rabbit to give the in vitro total antiplasmin. The mean value for 14 rabbits was 4,068.6 units.In order to estimate the total antiplasmin in vivo, UK solution was infused into rabbits. The infusion speed was multiplied by the time of the first appearance of fibrinolytic activity to give the total antiplasmin, although when the infusion speed was low, fibrinolytic activity did not appear during infusion. The mean in vivo total antiplasmin calculated for 6 cases where the infusion speed was high and fibrinolytic activity was observed, was 28,699.8 units, i.e. about 7 (range, 3-11) times the in vitro value.

Immediate aspiration of the drug infused via central venous catheter through the distally positioned central venous dialysis catheter: An experimental study

2020 ◽  
pp. 112972982092455
Author(s):  
Vaidas Vicka ◽  
Alvita Vickiene ◽  
Jonas Tutkus ◽  
Jokubas Stanaitis ◽  
Rimante Bandzeviciute ◽  
...  
Keyword(s):  
Central Venous Catheter ◽  
Experimental Model ◽  
Superior Vena Cava ◽  
Superior Vena ◽  
Vena Cava ◽  
Venous Catheter ◽  
Dialysis Catheter ◽  
Central Venous ◽  
Arterial Lumen ◽  
Infusion Speed

Objectives: The aim of this study was to construct an experimental model replicating blood flow within human superior vena cava and to determine the degree of the immediate aspiration of the drug introduced via central venous catheter through the distally positioned dialysis catheter. Methods: A model replicating superior vena cava was built, catheters were inserted into the model, placing the orifice of the central venous catheter in positions regarding the orifice of the arterial lumen in central venous dialysis catheter (from +2 to −8 cm). Methylene blue was used as a tracer, and the concentration was determined by ultraviolet-visible spectroscopy. Four different sets of samples were generated according to infusion and aspiration speeds: continuous–slow, continuous–fast, bolus–slow, and bolus–fast. Results: The concentration of the tracer was related to the distance between the catheter tips, representing a bimodal dependence. When the central venous catheter was placed distally to the central venous dialysis catheter, the aspiration of the tracer was minimal. When withdrawing the central venous catheter proximally, the aspiration of the tracer increased, reaching its peak at −4 cm with aspiration rates form 4.2% to 140.7%. Furthermore, the infusion speed of the tracer had more effect on the aspirated concentrations than the aspiration speed. Conclusion: Findings of our experimental model suggest that concentration of aspired drug is effected by the distance between the central venous catheter and central venous dialysis catheter, being lowest when the drug is infused distally to central venous dialysis catheter. Furthermore, the concentration of the tracer is directly proportional to the infusion speed and far less effected by the aspiration rate of the drug.

The Design of Electronic Monitor Used in Hospital

2013 ◽  
Vol 392 ◽  
pp. 697-701
Author(s):  
Jun Feng Dai ◽  
Li Hui Fu
Keyword(s):  
Medical Staff ◽  
Photoelectric Method ◽  
Current Time ◽  
Improve Working ◽  
Monitoring Instrument ◽  
Hospital Inpatients ◽  
Working Efficiency ◽  
Infusion Speed

An electronic monitor for hospital inpatients is designed in this paper. Patients can give a calling signal by button, and the monitor can detect and display the infusion speed and give a alarm in time when the speed is too fast or too slow, in addition, it also can set various time for activity to inform medical staff. The whole system is divided into the host and the extension, the host display the current time and set various time for activities by DS1302 chip, the extension give the calling signal by keyboard, the host receive it through communication and display the bed number, the infusion speed is detected through the photoelectric method and is send to the extension for display and alarm. The monitoring instrument has great application value which can avoid failure during the process of transfusion and improve working efficiency.

Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate

2009 ◽  
Vol 89 (3) ◽  
pp. 309-316 ◽  
Author(s):  
Ingrid Pabinger ◽  
◽  
Andreas Tiede ◽  
Uwe Kalina ◽  
Sigurd Knaub ◽  
...  
Keyword(s):  
Prothrombin Complex Concentrate ◽  
Infusion Speed

The Design of Infusion Monitoring System Based on STM32 Microcontroller

2013 ◽  
Vol 756-759 ◽  
pp. 395-398
Author(s):  
Zhi Hui Xu ◽  
Wei Zhong Li ◽  
Yong Jun Xiao
Keyword(s):  
Monitoring System ◽  
High Reliability ◽  
High Accuracy ◽  
Manual Adjustment ◽  
Infusion Speed

conventional manual adjustment to control the drop speed in clinical infusion has more unadvantageous and cannot realize automatic controlling and monitoring of the infusion speed. According to this condition, the infusion monitoring system is designed based on the STM32 microcontroller and one pair of infrared emitting and receiving diode, and the experimental is done. The result shows that this designed monitoring system can reach high accuracy, high reliability and low adjust time.

Effect of infusion speed of 7.5% hypertonic saline on brain edema in patients with craniocerebral injury: An experimental study

Gene ◽  
2018 ◽  
Vol 665 ◽  
pp. 201-207 ◽  
Author(s):  
Zhenzhen Jiang ◽  
Hongmei Xu ◽  
Meilin Wang ◽  
Zefu Li ◽  
Xinyang Su ◽  
...  
Keyword(s):  
Experimental Study ◽  
Brain Edema ◽  
Hypertonic Saline ◽  
Craniocerebral Injury ◽  
Infusion Speed
Sign in / Sign up

Export Citation Format

Share Document